PMEL and melanoma: Tebentafusp, an immune melanoma-associated-antigen (gp100)-targeting anti-CD3 / T-cell receptors (TCRs) bispecific fusion protein, has been designed to guide T lymphocytes to kill gp100-expressing UVM cells, and Tebentafusp results in a longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma [7].